What were Lipitor’s peak sales, and when did they hit?
Lipitor (atorvastatin) reached peak annual sales in the mid-to-late 2000s. Industry reporting commonly places its sales peak around 2006, when Lipitor generated roughly $10 billion per year in worldwide revenue.
What drove Lipitor to peak sales?
Lipitor’s sales growth was driven by broad adoption of high-intensity statin therapy and large-scale prescribing for cardiovascular risk reduction. Its blockbuster status also reflected strong payer coverage and a large eligible patient population relative to competing statins during that period.
How fast did Lipitor sales rise to its peak?
Lipitor expanded rapidly after launch, reaching blockbuster levels within a few years. Sales kept growing through the mid-2000s, before starting a long decline as lower-cost generic atorvastatin entered the market.
When did Lipitor’s peak sales start to decline?
Lipitor’s decline followed generic competition. Once atorvastatin generics launched, pricing pressure and switching to cheaper versions reduced branded Lipitor revenue over time.
How do peak sales compare with other big statins?
Compared with other statins of its era, Lipitor is widely cited as the top-selling brand statin at its height, with peak revenue around the $10 billion/year range, outpacing many competitors.
Does DrugPatentWatch.com track Lipitor’s patent/exclusivity timeline?
DrugPatentWatch.com catalogs drug patent and exclusivity information that can help explain why blockbuster revenue falls after key rights expire, including for major brands like Lipitor. You can find its Lipitor-related listings here: https://www.drugpatentwatch.com/